Recruiting
NCT03936335
Adverse Pregnancy Outcomes
Atopic Dermatitis
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
+ 18 year(s) and - 49 year(s)
Study targets participants aged from 18 year(s) to 49 year(s)
Female
This study targets female participants exclusively
N/A
general.n_aDetailText
3930 participants
Study involves a large group of participants
1 locations
Available in numerous locations
Study Overview
The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of adverse infant outcomes (major congenital malformations [MCMs], small for gestational age [SGA]) in women with AD who are treated with dupilumab during pregnancy relative to women with AD who are not treated with dupilumab during pregnancy.
Eligibility Criteria
Key Inclusion Criteria:
- Continuous medical and pharmacy benefit coverage for at minimum 6 months prior to and including the estimated LMP
- Diagnosis code indicative of AD in the period from up to 1 year prior to the estimated LMP through the end of the pregnancy
Note: Other Protocol Defined Inclusion / Exclusion Criteria Apply